|
Variables
|
Learning cohort [cases (%)]
|
Validation cohort [cases (%)]
|
|---|
|
High expression
|
Low expression
|
P*
|
High expression
|
Low expression
|
P*
|
|---|
|
Age (years)
|
0.775
| | |
0.547
|
|
≤ 55a
|
22 (40.7)
|
32 (59.3)
| |
10 (40.0)
|
15 (60.0)
| |
|
> 55
|
19 (43.1)
|
25 (56.9)
| |
8 (38.0)
|
13 (62.0)
| |
|
Gender
|
0.501
| | |
0.709
|
|
Male
|
34 (41.5)
|
48 (58.5)
| |
15 (36.8)
|
23 (63.2)
| |
|
Female
|
7 (43.8)
|
9 (56.2)
| |
3 (37.5)
|
5 (62.5)
| |
|
WHO grade
|
0.719
| | |
0.660
|
|
G1
|
11 (45.8)
|
13 (54.2)
| |
4 (36.4)
|
7 (63.6)
| |
|
G2
|
20 (40.0)
|
30 (60.0)
| |
8 (40.0)
|
12 (60.0)
| |
|
G3/4
|
10 (41.7)
|
14 (58.3)
| |
6 (40.0)
|
9 (60.0)
| |
|
Tumor size (cm)
|
0.640
| | |
0.387
|
|
≤ 6b
|
22 (39.3)
|
34 (60.7)
| |
13 (40.7)
|
19 (59.3)
| |
|
> 6
|
19 (45.2)
|
23 (54.8)
| |
5 (35.8)
|
9 (64.2)
| |
|
T category
|
0.541
| | |
0.174
|
|
T2
|
5 (41.7)
|
7 (58.3)
| |
6 (50.0)
|
6 (50.0)
| |
|
T3
|
14 (40.0)
|
21 (60.0)
| |
6 (33.3)
|
12 (66.7)
| |
|
T4
|
22 (43.1)
|
29 (56.9)
| |
6 (37.5)
|
10 (62.5)
| |
|
N category
|
0.622
| | |
0.328
|
|
N0
|
8 (47.1)
|
9 (52.9)
| |
6 (42.9)
|
8 (57.1)
| |
|
N1
|
33 (40.8)
|
48 (59.2)
| |
12 (37.5)
|
20 (62.5)
| |
|
M category
|
0.352
| | |
0.302
|
|
M0
|
27 (45.8)
|
32 (54.2)
| |
10 (41.7)
|
14 (58.3)
| |
|
M1-lym
|
14 (35.9)
|
25 (64.1)
| |
8 (31.9)
|
14 (68.1)
| |
|
CRT response
|
0.007
| | |
0.003
|
|
CR
|
14 (73.7)
|
5 (26.3)
| |
8 (80.0)
|
2 (20.0)
| |
|
Not CR
|
27 (34.2)
|
52 (65.8)
| |
10 (27.8)
|
26 (72.2)
| |
- ESCC esophageal squamous cell carcinoma, T tumor, N node, M metastases, M1-lym distant lymph node metastasis, CR complete response
- * χ2 test
- aMean age
- bMean tumor size
